Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MARIO: IV echinocandin followed by oral ibrexafungerp vs IV echinocandin followed by oral fluconazole in candidemia/invasive candidiasis
2022-000648-32Phase 3Active
- Sponsor
- SCYNEXIS, Inc.
- Start
- Jul 2022
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ibrexafungerp in candidemia and invasive candidiasis (2 arms), sponsored by SCYNEXIS, Inc. Primary endpoint: All-cause mortality at Day 30. Started Jul 2022; status: active.
02
Drugs
ibrexafungerp
03
Conditions
candidemiainvasive candidiasis
Beyond the preview
Go deeper on 2022-000648-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-000648-32.